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Halothane (2-bromo-2 -chloro- l , I , 1-trifluoro-
ethane) is the most popular inhalation agent in today's 
anesthetic prac tice. Its desirable properties include 
high potency, nonflammabil ity, patient acceptance, 
a low incidence of nausea and vomiting, ability to 
produce bronchod ilatation, and ease of mainten ance. 
Prior to its introduction in 1956, it was subjected 
to an intense examination for both general and he-
patic toxicity. Although these investigations disclosed 
no evidence of adverse effects, reports of liver 
dysfunction after halothane administ ra tion have ap-
peared constantly in the literature. Thus, although 
the general safety of this drug continues to be excel-
lent, the clinician is confronted with a dilemma each 
time he elects to use this agent. I hope to give some 
perspective to this question . 
The first thing to understand is that administra-
tion of any of the anesthetics currently in use may 
be followed by mild and reversible evidence of liver 
derangement. Studies conducted over twenty years 
ago showed that administration of diethyl ether or 
cyclopropane was followed by significant brom-
sulfalein retention, a phenomenon also observed 
when spinal anesthesia was used . Subsequent in-
vestigations have shown this to be true in the case 
of methoxyflu rane and halothane. Other work has 
indicated that clearance of indocyanine green ( ICG ) 
is markedly diminished during anes thesia. It would 
thus appear that all anesthetics have the ability to 
produce mild and reversible evidence of hepatic 
abnormalities; findings which are probably of no 
physiologic significance. This property is shared by 
halothane. 
H alothane also produces reversible abnormali-
ties of hepatic mitochondrial function. Oxygen up-
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take of mitochondria stimulated by adenosine di-
phosphate is diminished in the presence of clinically 
effec ti ve concent rations of halothane. Haloth ane, 
however, is no different from methoxyflurane, diethyl 
ether, and ethrane which also produce these ch anges. 
Thus, although halothane has spec ific metabolic ef-
fects , it shares these in common with other inhalation 
agents. 
Perh aps haloth ane exerts its effects th rough 
altered hepatic circulation . Studies performed in man 
during halothane anesthesia indicate that splanchnic 
blood fl ow decreases as mean arterial pressure is 
lowered; !CG clearance is diminished also. How-
ever, when arteri al carbon dioxide tension is ele-
vated, spl anchnic vasodilatation occurs and splanch-
nic blood fl ow is increased. In spite of the return 
of blood flow to normal, ICG clearance remains 
depressed . Cyclopropane, on the other hand, in-
creases arterial pressure while hepatic blood flow 
is decreased. Again, ICG clearance is lowered. When 
hexa methonium is infused, splanchnic vascular re-
sistance decreases and spl anchnic flow is elevated. As 
in the case of halothane, the return of hepatic per-
fusion to normal does not result in a normal ICG 
clearance . Agai n, we must consider the abnormality 
in !CG clearance to be a nonspecific anesthetic ef-
fect rather than the pathologic manifestation of a 
low perfusion state. We must also realize that halo-
th ane does not have a specific effect , and that this 
phenomenon is observed with all the inhalation 
agents. 
It is clear that the major question which must 
be answered for any anesthetic agent concerns its 
overall safe ty . It is because of this problem that a 
retrospective study of anesthetic safety during the 
years 1959-1963 was undertaken. This study, known 
as the National H alothane Study, evaluated the 
records of 865,5 15 anesthetics. In this group, I 6,840 
deaths were reported of which 11 ,289 underwent 
autopsy. There were two significant questions which 
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were posed: ( 1) Were there differences among 
anesthetic agents and techniques in overall death 
rates and in the incidence of massive hepatic necro-
sis? (2) Were there any differences among anes-
thetic agents and techniques in the death rate or in-
cidence of massive hepatic necrosis when surgery in 
the biliary tract was performed? The overall results 
of the study suggested that halothane was at least as 
safe as the other agents examined . Furthermore, it 
was no less safe th an the other drugs when biliary 
surgery was performed. 
Although the data suggested that halothane's 
safety was at least equal to th at of other drugs and 
techniques, a certain nagging doubt persisted . Most 
of the cases of hepatic necrosis were obviously 
caused by factors such as hemorrhagic shock, sepsis, 
or previous transfusion. However, in nine cases no 
etiology was obvious and of these, seven had re-
ceived halothane . Furthermore, four of these seven 
had been exposed previously to halothane. It must 
be realized that the National Halothane Study had 
an element of volunteer bias in that several of the 
unexplained cases of massive hepatic necrosis had 
already been published, and most probably the 
institution volunteered to participate in the study 
because of this. Nonetheless, the possibility was con-
sidered that halothane might be responsible for cer-
tain cases of hepat ic dysfunction . 
In subsequent years, a number of events were 
reported which indicated that exposure of unoperated 
man to extremely low concentrations of the agent 
might rarely produce hepatic abnormalities. It was 
from a consideration of such events that the con-
cept of halothane hypersensitivity arose. This theory 
stated that halothane is not a direct hepatotoxin. In 
the rare cases (the incidence of unexplained hepatic 
necrosis following halothane was 1 :35,000), the in-
dividual might be hypersensitive or "allergic" to the 
agent. This would explain the increased likelihood of 
observing the phenomenon after more than one ex-
posure, and might also explain the occurrence in un-
operated man receiving sub-anesthetic concentrations 
of the drug. Additional support to this theory was 
evidence of lymphocyte transformation produced by 
incubating lymphocytes of affected man with halo-
thane. It should be noted that many individu als with 
what appears to be halothane-induced hepatitis did 
not show positive lymphocyte transformation. Fur-
thermore, occasional false positive results have been 
reported . Thus, although the hypersensitivity theory 
is not unreasonable, it should not be considered to 
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be the sole explanation of this unfortunate phenome-
non. 
We have recently studied the concentrations of · 
immunoglobulins in man following surgery per- . 
formed during halothane anesthesia. Observations 
were made prior to and up to 30 days after surgery; 
data obtained was compared with similar studies 
when anesthesia was provided by nitrous oxide sup-
plemented with narcotic. No significant changes 
were produced by either nitrous oxide-narcotic or 
nitrous oxide-halothane. In another group of in-
dividuals receiving halothane anesthesia, measure-
ments of serum glutamic oxaloacetic transaminase 
concentratibn and bromsulfalein retention accom-
panied the assays of immunoglobulin concentrations. 
Although transient abnormalities of hepatic function 
were observed, no alterations in the immunoglobulin 
pattern were noted during observations lasting as 
long as 60 days. 
Although these data do not definitely rule out 
an immunologic basis for halothane-induced hepatic 
necrosis, they do suggest that a systematic immu-
nologic abnormality does not occur usually follow-
ing anesthesia with this agent. Furthermore , they 
indicate that short-lived abnormalities of hepatic 
function following halothane anesthesia are similar 
to those observed with other anesthetic drugs and 
are not the result of immunologic factors . Finally, 
these observations furnish a base line should the 
opportunity arise to obtain samples from a patient 
with severe hepatic failure following halothane anes-
thesia. 
Are there any other mechanisms which might 
be responsible? In the past few years, increasing 
emphasis has been placed on the ability of the he-
patic microsomal system to detoxify a wide variety 
of drugs. Many of the inhalation anesthetics, among 
them halothane, are so metabolized . Furthermore, 
prior exposure to halothane produces enzyme in-
duction which results in a more rapid rate of halo-
thane biodegradation. It is not inconceivable that 
abnormal pathways of biodegradation might produce 
toxic metabolites which could result in hepatic necro-
sis. 
At the present time, the evidence is not clear as 
to what might be the mechanism for the extremely 
rare case of halothane-induced hepatic necrosis. In-
deed, it is still a moot point as to whether this entity 
can be definitely proven to exist. However, the 
answer to the question of this lecture can be easily 
made. The National Halothane Study supplied excel-
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Jent data indicating that in the overwhelming ma-
jority of patients the drug is as safe as any currently 
used. I would sugges t th at the mai n factor determining 
patient safety is the individual ad ministering the 
anesthetic rather than the specific agent itself. How-
ever, although the drug is exceedingly safe, a small 
number of patients may be at risk . It is the task of 
future investigation to delineate these individuals so 
as to prevent the occurrence of this syndrome. 
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